No connection

Search Results

ABBV vs EHC

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
EHC
Encompass Health Corporation
BULLISH
Price
$101.98
Market Cap
$10.14B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
EHC
18.37
Forward P/E
ABBV
15.42
EHC
15.74
P/B Ratio
ABBV
-146.66
EHC
4.18
P/S Ratio
ABBV
6.5
EHC
1.71
EV/EBITDA
ABBV
15.27
EHC
9.86

Profitability

Gross Margin
ABBV
71.46%
EHC
43.21%
Operating Margin
ABBV
35.5%
EHC
18.35%
Profit Margin
ABBV
4.0%
EHC
9.54%
ROE
ABBV
137.96%
EHC
24.82%
ROA
ABBV
9.59%
EHC
9.66%

Growth

Revenue Growth
ABBV
9.1%
EHC
9.9%
Earnings Growth
ABBV
-88.7%
EHC
21.2%

Financial Health

Debt/Equity
ABBV
--
EHC
0.83
Current Ratio
ABBV
0.72
EHC
1.08
Quick Ratio
ABBV
0.47
EHC
0.83

Dividends

Dividend Yield
ABBV
3.05%
EHC
0.75%
Payout Ratio
ABBV
490.15%
EHC
12.97%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
EHC BULLISH

EHC presents a stable financial profile with a Piotroski F-Score of 4/9 and a significant valuation gap between its defensive Graham Number ($55.18) and growth-based Intrinsic Value ($163.72). The company exhibits exceptional operational efficiency with an ROE of 24.82% and a highly attractive PEG ratio of 0.41, suggesting the stock is undervalued relative to its earnings growth. While insider sentiment is bearish and technical trends are currently weak, the long-term fundamental trajectory is supported by a 25-quarter track record of consistent earnings beats. The current price of $101.98 represents a reasonable entry point given the analyst target of $142.73.

Strengths
Exceptional earnings track record with consistent beats over 25 quarters
Very low PEG ratio (0.41) indicating strong growth at a reasonable price
High Return on Equity (24.82%) demonstrating efficient capital use
Risks
Bearish insider activity with significant selling by the CEO and other officers
Weak technical trend (0/100) indicating short-term price momentum is negative
Tight liquidity with a current ratio of 1.08

Compare Another Pair

ABBV vs EHC: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Encompass Health Corporation (EHC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile